2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human multiple myeloma cell lines

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

3

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P991155
    Ramantamig

    JNJ-79635322; JNJ-5322

    		 CD3 TNF Receptor Cancer
    Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
    Ramantamig
  • HY-P99798
    Pacanalotamab

    AMG 420; BI-836909

    		 CD3 Cancer
    Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
    Pacanalotamab
  • HY-172614
    RK-0080552

    RK-552

    		 Histone Methyltransferase Apoptosis Cancer
    RK-0080552 (RK-552) is a NSD2 inhibitor with an IC50 of 0.11 μM, and it exhibits selectivity over histone methyltransferases G9a (IC50: 1.2 μM) and SET7/9 (IC50: >50 μM). RK-0080552 functionally inhibits NSD2 histone methyltransferase activity, reduces the dimethylation level of histone H3 lysine 36, suppresses IRF4 transcription, induces apoptosis and triggers cell death. RK-0080552 inhibits the growth of xenograft tumors and prolongs host survival. RK-0080552 is available for the research of multiple myeloma .
    RK-0080552
  • HY-E70719
    FGFR3 K650E Recombinant Human Active Protein Kinase

    		FGFR Cancer
    FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 K650E is a mutant of FGFR3 that may be present in multiple myeloma cell lines. FGFR3 K650E Recombinant Human Active Protein Kinase is a recombinant FGFR3 K650E protein that can be used to study FGFR3 K650E-related functions .
    FGFR3 K650E Recombinant Human Active Protein Kinase
  • HY-P992483
    VIS832

    		Transmembrane Glycoprotein Cancer
    VIS832 is an anti-CD138 monoclonal antibody. VIS832 induces antibody-dependent cellular cytotoxicity. VIS832 inhibits the growth of disseminated multiple myeloma tumors in vivo. VIS832 exerts anti-tumor effects on multiple myeloma in combination with Lenalidomide (HY-A0003) or Bortezomib (HY-10227). VIS832 can be used in research related to multiple myeloma .
    VIS832

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: